The Shutdown Spectrum: A Real-World Look at Hormonal Recovery

The Bill Always Comes Due

Everyone loves to talk about the cycle. The new PRs and the fuller look in the mirror are the fun part. But hardly anyone wants to talk about the weeks or months after, when users describe low libido and flat motivation, and many say they struggle to hold onto the muscle they built.

That's the hormonal bill coming due.

Forum discussions often lump everything into one bucket. But the hormonal impact of a classic testosterone cycle is very different from a SARM cycle, and most of the peptides people use don't act on the same hormone system at all. This page, part of our long-term effects comparison across compound classes, covers how each class suppresses the hormonal axis and how recovery compares. Sperm and fertility recovery get their own page on reproductive health effects.

Total Shutdown: The Anabolic Steroid Playbook

Exogenous androgens such as testosterone and trenbolone, or oral steroids like Dianabol, tell the body's natural hormone production to stand down. Your Hypothalamic-Pituitary-Testicular Axis (HPTA) is a finely tuned feedback loop. The hypothalamus releases GnRH, telling the pituitary to release LH and FSH, which in turn tell your testes to produce testosterone.

Injecting a supraphysiologic dose of testosterone is like turning the thermostat in your house up to 120 degrees. The system responds by switching the furnace off. LH and FSH production falls to very low levels, and your own testosterone production largely stops. A 2020 Sydney study found clearly suppressed reproductive hormones in 41 current users compared with non-users.

This is why lifters treat Post-Cycle Therapy (PCT) as standard after a steroid cycle. PCT usually means SERMs such as clomiphene (Clomid) or tamoxifen (Nolvadex), prescription medicines that block estrogen feedback so the pituitary releases LH and FSH again. A 2014 review in Fertility and Sterility lists SERMs and hCG as treatment options, along with supervised testosterone replacement, but found no studies good enough to pool.

Recovery is slow. We're not talking about bouncing back in a week. In the 2020 study, past users (at least 3 months off, median about 300 days) looked like non-users on most measures, but mean recovery took about 11 months for LH, and the authors put full recovery at 6 to 18 months. Testicular volume stayed smaller. A 2015 study of former long-term users at McLean Hospital was less reassuring: 5 of 19 untreated men still had testosterone below 200 ng/dL after 3 to 26 months off. Whether shutdown is ever permanent isn't settled, but prolonged low testosterone is a documented risk for long-term users.

Suppression, Not Annihilation: The SARM Compromise

Then we have Selective Androgen Receptor Modulators (SARMs). The original pitch for these compounds was the muscle-building upside of steroids without downsides like prostate growth or HPTA shutdown. The reality is messier.

At the doses studied, SARMs are less suppressive than typical steroid cycles, but they are still suppressive. The clearest human data come from a 2013 trial of LGD-4033 in 76 healthy men: 21 days at 0.1, 0.3 or 1.0 mg per day lowered total testosterone in a dose-dependent way. FSH and free testosterone fell significantly only at the 1.0 mg dose. Community guides often claim that a low-dose run of Ostarine (MK-2866) drops testosterone by 20-30%, while LGD-4033 or RAD-140 at the higher doses users report can cut it by 70% or more. We couldn't trace either figure to a study; they come from self-reported bloodwork.

The difference is a matter of degree. With SARMs, it's typically suppression, not the near-complete shutdown seen with steroids. In the LGD-4033 trial, hormone levels returned to baseline after the drug was stopped, within the 5-week follow-up and without any PCT. Users commonly describe higher doses and longer cycles than that trial tested, so the result may not carry over. Many community protocols include a 4-week SERM-based PCT after a SARM cycle; no trial has tested whether it speeds recovery.

The big catch with SARMs is the lack of long-term data. Testosterone has decades of clinical use behind it. As of October 2026, no SARM is FDA-approved, and the published trials ran for weeks to months, so anyone using them is part of an uncontrolled experiment. The recovery might be faster, but the long-term consequences are still unknown. We cover other systemic risks in our cardiovascular risk comparison.

Changing the Channel: How Peptides Sidestep the Problem

Peptides are a different case. The ones covered here don't supply an androgen, so they don't trigger the same negative feedback on the HPTA. But their effect on the reproductive axis has barely been measured, so "no known suppression" here mostly means nobody has looked closely.

Growth Hormone Peptides (GHRHs & GHRPs)

The most popular class is growth hormone secretagogues. This includes GHRH analogs like CJC-1295 and GHRPs like ipamorelin or GHRP-2. Their job is to stimulate the pituitary gland to release more of the body's own growth hormone. Think of ipamorelin as knocking on the pituitary's door and CJC-1295 as telling it how long to keep the door open. This site rates the evidence for all three as moderate: the human data are limited, and none of it covers long-term use in healthy adults.

This signaling cascade runs through the GH axis, not the HPTA that governs testosterone production. Users commonly run CJC-1295 (usually the no-DAC form, Mod GRF 1-29) with ipamorelin hoping for better sleep and recovery, though controlled trials haven't shown those outcomes. We haven't found a human study reporting suppressed gonadotropins or testosterone with these compounds, and users don't describe needing PCT after them. But the trials were small and built around GH and IGF-1, so the reproductive axis was rarely the focus.

The class isn't hormonally neutral, either. In a 2-year trial in 65 healthy older adults, 25 mg per day of oral MK-677 (another GH secretagogue) raised cortisol and fasting glucose and lowered insulin sensitivity.

Healing and Systemic Peptides

The picture is simpler, though even less studied, with BPC-157 and TB-500. Neither is designed to act on the reproductive hormone system. In rodent studies, BPC-157's best-described mechanism involves increased signaling through VEGFR2, the main receptor for vascular endothelial growth factor (VEGF), which helps build new blood vessels at an injury site. TB-500 is a short fragment of thymosin beta-4, and the cell-migration effects attributed to it through actin binding come from cell and animal studies, mostly of the full-length protein.

The evidence behind both is thin. This site rates BPC-157 as emerging: the rodent data are consistent, but 35 of the 36 studies in a 2025 systematic review were preclinical, and its authors found no clinical safety data. TB-500 is rated preliminary; as of October 2026, FDA says it has identified no human exposure data for the fragment. No study we found has measured reproductive hormones in people using either one. The common claim that they won't suppress you and don't need PCT rests on mechanism and user reports, not measurement.

The Recovery Timelines at a Glance

Laid side by side, the differences are clear. The question here is less which compound is "strongest" in a vacuum and more what recovery cost you're signing up for.

Looking at this, the choice is partly about recovery time: after steroids, studies of past users put the recovery tail in months.

Choose Your Tools, Choose Your Recovery

These compounds do different jobs, the way a hammer and a screwdriver do. Anabolic steroids are a sledgehammer: strong but crude, and they leave a mark on your endocrine system that takes months to fade. SARMs are like a smaller hammer. They still cause suppression, but in the short trial above, hormone levels came back within weeks.

Peptides are a different toolkit entirely. GH secretagogues target pituitary GH release. BPC-157 and TB-500 are used for tissue repair. Neither group has shown HPTA suppression, but neither has been studied closely enough to rule it out, and GH secretagogues bring hormonal effects of their own.

Alongside the question of results, it helps to ask what the total cost is and what kind of recovery you can realistically manage. Mood is part of that cost. In the 2015 McLean study, 7 of 24 former long-term steroid users had a major depressive episode during withdrawal, a topic our psychological effects comparison covers in more detail.

What we still don't know

• Whether SARM suppression at user-reported doses recovers as quickly as it did in the LGD-4033 trial.
• Whether PCT actually shortens recovery after steroids or SARMs.
• Whether GH secretagogues, BPC-157 or TB-500 change LH, FSH or testosterone at all.